Compare Illumina, Inc. (ILMN) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Teladoc Health Inc — how do they compare? Illumina, Inc. trades at $192.3 (market cap $29.12B), while Teladoc Health Inc trades at $6.78 (market cap $1.24B). The key difference: Illumina, Inc. is far larger — about 23.5× Teladoc Health Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Teladoc Health Inc nearer its low. Which is the better fit depends on your goals.
| ILMN | TDOC | |
|---|---|---|
Market Cap | $29.12B | $1.24B |
Sector | Health | Health |
52-Week High | $205.10 | $9.72 |
52-Week Low | $91.00 | $4.47 |
Enterprise Value | $30.48B | $1.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $191.79, up 2.04% today, with a neutral technical signal and strong fundamental recovery. The stock shows bullish moving averages but faces resistance near $194. Recent earnings beats and a return to profitability in 2025, with $850M net income, highlight operational turnaround. Revenue remains stable around $4.3B, supported by robust gross margins of 66.38%.
Outlook is positive with analyst consensus Buy rating and $201.58 price target, though high P/E of 35.98 poses valuation risk. Key opportunities include sequencing demand and AI partnerships, while risks involve debt levels and competitive pressures. Institutional activity is mixed, with some funds increasing stakes amid earnings momentum.
Teladoc Health (TDOC) trades at $7.08, down 0.7% for the day, with a bearish technical signal and negative earnings. The stock faces pressure from a recent 28% drop after Q2 2026 revenue missed estimates and full-year guidance was cut. Valuation metrics like P/S of 0.49 and EV/EBITDA of 6.96 appear low, but profitability remains weak with a -7.13% net income margin. Multiple law firms are investigating potential securities violations, adding to investor concerns.
The outlook is cautious due to ongoing losses and competitive pressures in virtual care. Risks include execution challenges at the BetterHelp unit and regulatory scrutiny. Analyst consensus is mixed with a $8.88 price target, but near-term volatility is likely amid negative sentiment and fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
